IFS Product Owner

Company description: Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patients cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world''s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica''s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Job description: Join Us in Changing Lives At?OXB, our people are at the heart of everything we do.?Were?on a mission to enable life-changing therapies to reach patients around the worldand?were?looking for passionate individuals who embody our core values every day: ?Responsible, Responsive, Resilient, and Respectful. We are currently hiring an IFS Product Owner to join the Information Systems (IS) team. In this role, you will provide strategic leadership for the IFS product roadmap, ensuring its alignment with organisational objectives, timely and high-quality delivery and adherence to GMP compliance standards where needed, playing a key part in advancing our mission and making a real difference. Your responsibilities in this role would be: Being the internal & external expert within OXB for the UKs Enterprise Resource Planning (ERP) system Partnering with business process owners to understand business requirements Owning the solution strategy for the ERP system Understanding, maintaining and developing simple configuration for the ERP system Leading the OXB IFS community regarding planned ERP system update activities Collaborating between multiple departments to ensure ERP functionality and benefits are being realised by the business Collaborating with Validation and Quality Assurance leads in the preparation and execution of system changes Ensuring Quality Management and Validation requirements are met within delivery of Good Practice (GxP) projects We are looking for: A degree level education within Software development, Life Sciences or equivalent work experience Experience working with an ERP system in a regulated industry. GxP experience is essential Experience of working on an upgrade from an IFS Apps version to IFS Cloud (preferred) Experience managing complex needs of stakeholder groups, explaining what is possible and translation to system requirements Readiness to play a key role within the IS Team and cross departmentally to ensure that IFS and other GxP systems are being effectively improved Ability to prioritise and plan the implementation of work About Us: OXB is a quality and innovation-led viral vector CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, we have more than?30?years of experience in viral vectors; the driving force behind?the majority of?gene therapies. OXB collaborates with some of the worlds most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing?expertise?in lentivirus, adeno-associated virus (AAV)?and adenoviral vectors. OXBs world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods, and depth of regulatory?expertise. Why Join Us? ???Competitive total reward packages ???Wellbeing programmes?that support your mental and physical health ???Career development opportunities?to help you grow and thrive ???Supportive, inclusive, and collaborative culture ???State-of-the-art labs and manufacturing facilities ???A company that lives its values:? Responsible, Responsive, Resilient, Respect We want you to feel inspired every day. At?OXB,?were?future-focused and growing fast. We succeed togetherthrough passion, commitment, and teamwork. Ready to Make a Difference? Collaborate. Contribute. Change lives . We offer: Oxford Biomedica is a quality and innovation-led viral vector CDMO that enables its clients to deliver life-changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, Oxford Biomedica has more than 25 years of experience in viral vectors, the driving force behind the majority of gene therapies. Cell and gene therapy is the treatment of disease by the delivery of therapeutic genetic material (DNA or RNA), into a patients cells. One highly effective approach to delivering genetic information is to re-engineer existing viruses to be safe delivery vehicles (vectors) to insert the genetic material into patients cells. This can be achieved either by directly administering the vector to the patient (often referred to as in vivo gene therapy), or by first introducing the genetic material to cells or tissue outside of the body, before administering the cells or tissue into the patient (often referred to as ex vivo gene therapy or gene-modified cell therapy). Oxford Biomedica collaborates with some of the world''s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica''s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise.55b20050-bc17-4e5d-bfce-3c406318dffc

Created: 2025-12-11